The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Follow AbbVie UK

Tags

Response To Announcement Of NHS England’s Plans To Be First In The World To Eliminate Hepatitis C

Press releases   •   Jan 26, 2018 08:46 GMT

MAIDENHEAD, UK, January 28, 2017 – We welcome NHS England’s announcement of their plans towards the elimination of hepatitis C in England and we are encouraged to see a commitment being made for the long-term.

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

Press releases   •   Dec 14, 2017 00:01 GMT

Phase III MURANO results presented for the first time as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta

Welsh Government renews commitment to eliminate hepatitis C with support from health organisations

Press releases   •   Dec 07, 2017 00:01 GMT

MAIDENHEAD, Dec. 07, 2017 – AbbVie is sponsoring a roundtable meeting, Chaired by The Hepatitis C Trust and sponsored by Ynys Môn Assembly Member, Rhun ap Iorwerth, to consider how the NHS in Wales can be supported to meet the Government’s commitment to eliminating hepatitis C as a major public health threat in Wales by 2030.

AbbVie 2017 National Sustainable NHS Award Winners Unveiled

AbbVie 2017 National Sustainable NHS Award Winners Unveiled

Press releases   •   Nov 28, 2017 14:00 GMT

AbbVie’s ‘Patients as Partners’ awards recognise those who have made an exceptional contribution to the lives of patients and contributed toward a more sustainable health service.

AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) accepted for use within NHS Scotland

Press releases   •   Nov 16, 2017 00:01 GMT

Scottish Medicines Consortium accepts MAVIRET® for the treatment of adults in Scotland with chronic hepatitis C virus (HCV) infection

MPs back call for Government commitment to eliminate hepatitis C by 2030

AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) recommended for use within NHS Wales

Press releases   •   Oct 20, 2017 00:01 BST

All Wales Medicines Strategy Group recommends MAVIRET® for the treatment of adults in Wales with chronic hepatitis C virus (HCV) infection

Health leaders and politicians call for hepatitis C elimination strategy in Northern Ireland

Press releases   •   Oct 17, 2017 00:01 BST

Elected Members of the Legislative Assembly and patient group representatives will meet with leading clinicians and service providers today to discuss the need for a region-wide strategy for the elimination of hepatitis C in Northern Ireland

NICE recommends access to AbbVie’s VENCLYXTO®▼ (venetoclax) to treat most common form of adult leukaemia in England via Cancer Drugs Fund

Press releases   •   Oct 05, 2017 00:01 BST

Today the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that AbbVie’s VENCLYXTO® (venetoclax) is made available to NHS patients with difficult-to-treat types of chronic lymphocytic leukaemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access agreement are followed.

AbbVie’s HUMIRA® (adalimumab) Approved by European Commission to Treat Paediatric Patients with Chronic Non-infectious Anterior Uveitis

Press releases   •   Sep 11, 2017 00:01 BST

Decision marks AbbVie’s HUMIRA® (adalimumab) as the only approved biologic treatment option in the European Union for paediatric patients from 2 years of age with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy

The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie’s glecaprevir/pibrentasvir

The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie’s glecaprevir/pibrentasvir

Press releases   •   Aug 16, 2017 00:01 BST

AbbVie, a global biopharmaceutical company, today announced The Lancet Infectious Diseases has published results from the Phase 3, single arm, open label, multicentre EXPEDITION-1 trial evaluating glecaprevir/pibrentasvir in chronic hepatitis C infected adult patients with genotypes 1, 2, 4, 5 or 6 and compensated cirrhosis.

Scotland first in the UK to make VENCLYXTO®▼ (venetoclax) routinely available for patients with most common form of adult leukaemia

Press releases   •   Aug 07, 2017 00:01 BST

Scottish Medicines Consortium accepts AbbVie’s venetoclax for routine prescribing across NHS Scotland, offering a new therapy option for patients with certain types of difficult-to-treat chronic lymphocytic Leukemia (CLL).

European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorisation for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Press releases   •   Jul 28, 2017 00:01 BST

MAVIRET is a new 8-week, pan-genotypic treatment for adult hepatitis C patients without cirrhosis and who are new to treatment

WORLD HEPATITIS DAY: London Assembly and health experts to agree priority actions needed to eliminate hepatitis C

Press releases   •   Jul 28, 2017 00:01 BST

Representatives from the London Assembly and local authorities in the Capital are set to meet with third sector and public health representatives in a roundtable meeting hosted by biopharmaceutical company, AbbVie, on World Hepatitis Day.

Experts Call for New focus on Value in NHS and Scaling up of Best Practice

Experts Call for New focus on Value in NHS and Scaling up of Best Practice

Press releases   •   Jul 19, 2017 00:01 BST

New report warns the NHS must reconsider its approach to value if it is to meet its productivity and efficiency saving targets and secure sustainability

2016 disclosure of AbbVie UK ‘Transfers of value’ to healthcare professionals and organisations

2016 disclosure of AbbVie UK ‘Transfers of value’ to healthcare professionals and organisations

Press releases   •   Jun 30, 2017 00:01 BST

Disclosure UK’, the central UK database for pharmaceutical industry transparency reporting, released its second full year of data on 30th June 2017.

Local health experts and MSPs call for focus on eliminating hepatitis C in Scotland

Press releases   •   Jun 27, 2017 00:01 BST

Local health experts and Members of the Scottish Parliament (MSPs) are meeting in Edinburgh to discuss what needs to be done to eliminate hepatitis C in Scotland by 2030